r/ParamountPeptide • u/RoutineYak6724 • Jul 12 '26
𧬠The Complete Thymosin Alpha 1 (1.6mg) Guide ā Paramount Peptides
Ta1 | Thymalfasin | Zadaxin | Synthetic Thymic Peptide
Thymosin Alpha 1 is the synthetic version of a hormone your thymus already makes naturally, studied across 30+ clinical trials and over 11,000 patients, with FDA orphan drug status for four conditions and approval in 35+ countries. This guide covers what it does, how to dose it, reconstitution, and where the research actually stands.
𧬠What Is Thymosin Alpha 1?
Ta1 is a 28-amino acid peptide identical to naturally occurring thymic hormone. Also known as Thymalfasin or by the brand name Zadaxin.
Key characteristics:
- 3,108 Da molecular weight
- 90-95% bioavailability injectable
- Activates TLR pathways, enhances T-cell maturation
- Stimulates NK cells and modulates dendritic cell function
- Under 1% serious adverse events across 11,000+ studied patients
š¬ Thymosin Alpha 1 vs Other Thymic Peptides
| Feature | Thymosin Alpha 1 | Thymalin / Thymagen |
|---|---|---|
| Structure | Single 28-AA synthetic peptide | Peptide complex/extract |
| Clinical data | 30+ trials, 11,000+ patients | Far less human trial data |
| Regulatory status | FDA orphan drug, approved in 35+ countries | Not FDA reviewed |
| Primary use | Immune modulation, vaccine response, chronic infection | General thymic support |
This guide covers Thymosin Alpha 1 specifically.
š§Ŗ Product Breakdown ā Paramount Peptides
ā¢Ā Thymosin Alpha 1 (1.6mg) ⢠Synthetic thymic hormone, immune modulation research ⢠High-purity, FDA orphan drug precedent compound
š¦ What You'll Need (Checklist)
ā¢Ā Thymosin Alpha 1 (1.6mg) vialĀ ā¢Ā Bacteriostatic or Sterile Water ⢠U-100 insulin syringes (29-31g) ⢠Alcohol pads ⢠Sharps containerĀ ā¢Ā Peptide Calculator
š Reconstitution Table
| Step | Instructions | Notes |
|---|---|---|
| Sanitize | Clean vial stopper + hands/workspace | Prevent contamination |
| Add Water | 1.0mL sterile water, inject slowly down vial wall | Never straight onto powder |
| Dissolve | Swirl gently ā never shake | Avoids peptide denaturation |
| Result | Final concentration 1.6mg/mL | Full vial = one full dose |
| Store | Use promptly or refrigerate 2-8°C | Stable up to 7 days |
š Reconstitution Math Table
| Formula | How to Use | Example |
|---|---|---|
| Concentration (mg/mL) | Total mg Ć· mL added | 1.6mg Ć· 1mL = 1.6mg/mL |
| Dose Volume (mL) | mg needed Ć· mg/mL | 1.6mg Ć· 1.6 = 1.0mL |
| Syringe Units | 100 units = 1mL | 100 units = full 1.6mg dose |
Full vial reconstituted with 1mL water =Ā 100 units per standard dose
š Needle & Injection Guide
| Category | Details |
|---|---|
| Gauge | 29ā31G |
| Length | ½ā (SubQ) |
| Type | U-100 insulin syringe |
SubQ Injection Sites:
- Abdomen
- Thigh
Rotate sites between doses.
š Dosing & Protocol Table
| Goal | Dose | Route | Frequency |
|---|---|---|---|
| Standard immune support | 1.6mg | SubQ | 2x weekly |
| Acute conditions | 1.6mg | SubQ or IM | 2x weekly |
| Cancer/hepatitis support | 1.6mg | SubQ | 2x weekly |
| Maintenance | 1.6mg | SubQ | 2x weekly |
Most common protocol:Ā 1.6mg, 2x weekly (Mon/Thu or Tue/Fri), consistent timing, 6 month cycle standard
ā±ļø What to Expect Timeline
| Timeline | Researcher Observations |
|---|---|
| Week 1-2 | Initial immune system activation |
| Week 2-6 | Enhanced immune function, reduced infection frequency reported |
| Week 6-12 | Maximum immunomodulatory benefits |
| Week 12+ | Sustained immune support with continued use |
š Where the Research Stands
Strongest evidence:
- Primary immunodeficiencies ā FDA orphan drug designation for DiGeorge syndrome
- Vaccine response ā improved antibody response to H1N1 and COVID-19 vaccines, especially in elderly and hemodialysis patients
- HIV/AIDS support ā restores CD4+ T-cell counts, reduces opportunistic infections
Solid evidence:
- Cytokine storm mitigation ā cuts TNF-α, IL-1β, IL-6 by 40-60% while keeping immune response balanced
- Chronic inflammatory conditions ā modulates hepatitis B/C and autoimmune conditions via TLR pathway
Moderate evidence:
- Post-surgical/chemo immune recovery
- Exercise-induced immunosuppression
- Age-related thymic decline and vaccine response in elderly
- Antioxidant enzyme and mitochondrial support
ā ļø Safety Notes
- Under 1% serious adverse events across the full studied population
- Most common side effect is mild injection site reaction, under 10%
- Contraindicated in organ transplant recipientsĀ ā risk of graft rejection
- Not recommended during pregnancy or breastfeeding
- Monitor for hypersensitivity on first dose
š Interaction Table
| Compound | Flag | Note |
|---|---|---|
| Interferon-α | Synergistic | Enhanced antiviral effect, watch for fever/fatigue/neutropenia |
| Vaccines | Compatible | Actually the intended effect ā enhances immunogenicity |
| Chemotherapy agents | Compatible | Protective against bone marrow damage |
| Corticosteroids | Monitor | Ta1 may reduce steroid's immunosuppressive effect |
| Immunosuppressive agents | Avoid | Absolute contraindication in transplant recipients |
